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PURPOSE: Increasedmurine doubleminute 2 (MDM2) expression, independent of p53 status, is associatedwith increased
cancer-specific mortality for men with prostate cancer treated with radiotherapy. We assessed MI-219, a small molecule
inhibitor ofMDM2with improved pharmacokinetics over nutlin-3, for sensitization of prostate cancer cells to radiotherapy and
androgen deprivation therapy, a standard treatment option for menwith high-risk prostate cancer. EXPERIMENTAL DESIGN:
The effect of MDM2 inhibition by MI-219 was assessed in vitro and in vivo with mouse xenograft models across multiple
prostate cancer cell lines containing varyingp53 functional status.RESULTS:MDM2 inhibition byMI-219 resulted in dose- and
time-dependent p53 activation and decreased clonogenic cell survival after radiation in a p53-dependent manner.
Mechanistically, radiosensitization following inhibition of MDM2 was largely the result of p53-dependent increases in
apoptosis and DNA damage as evidenced by Annexin V flow cytometry and γ-H2AX foci immunofluorescence. Similarly,
treatment with MI-219 enhanced response to antiandrogen therapy via a p53-dependent increase in apoptotic cell death.
Lastly, triple therapy with radiation, androgen deprivation therapy, andMI-219 decreased xenograft tumor growth compared
with any single- or double-agent treatment. CONCLUSION: MDM2 inhibition with MI-219 results in p53-dependent
sensitization of prostate cancer cells to radiation, antiandrogen therapy, and the combination. These findings supportMDM2
smallmolecule inhibitor therapyasa therapy intensificationstrategy to improveclinical outcomes inhigh-risk localizedprostate
cancer. TRANSLATIONAL RELEVANCE: The combination of radiotherapy and androgen deprivation therapy is a standard
treatment option for men with high-risk prostate cancer. Despite improvements in outcomes when androgen deprivation
therapy is added to radiation,menwith high-risk prostate cancer have significant risk for disease recurrence, progression, and
even death within the first 10 years following treatment. We demonstrate that treatment withMI-219 (an inhibitor of MDM2)
results in prostate cancer cell sensitization to radiation andandrogendeprivation therapy in vitro and in vivo. Triple therapywith
MI-219, radiation, and androgen deprivation therapy dramatically decreased tumor growth compared with any single- or
double-agent therapy. These findings provide evidence that inhibition of MDM2 is a viable means by which to enhance the2Conflicts: S. W. is a cofounder of Ascenta Therapeutics, which has licensed MI-219
and its analogues for clinical development. S. W. owns stock in Ascenta. The remaining
authors declare no conflict of interests in these studies.
3 These authors contributed equally.
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214 MDM2 Radiosensitizes p53-Intact Prostate Cancers Feng et al. Neoplasia Vol. 18, No. 4, 2016efficacy of both radiation and androgen deprivation therapy and thereby improve outcomes in the treatment of prostate
cancer. As such, further investigation is warranted to translate these findings to the clinical setting.
Neoplasia (2016) 18, 213–222Introduction
Prostate cancer is the second leading cause of cancer-specific death
among men [1]. The majority of deaths caused by prostate cancer occur
in patients initially diagnosed with high-risk disease as defined by the
National Comprehensive Cancer Network. In fact, patients with
high-risk disease have approximately a 14-fold increased risk of dying
from prostate cancer as compared with their low-risk counterparts [2].
Radiotherapy plus concurrent androgen deprivation therapy (ADT) is a
standard treatment modality for men diagnosed with high-risk prostate
cancer [3]. Multiple clinical trials have demonstrated improved patient
outcomes and improved patient survival when ADT is combined with
radiotherapy (RT) [2,4–6]. Despite the benefits obtained with the
addition of ADT to radiation for men with high-risk prostate cancer,
recurrence rates following treatment remain unacceptably high. In the
first 10 years, approximately 50% of these men may experience a
prostate-specific antigen (PSA) recurrence, 15%may developmetastatic
disease, and up to 12% may eventually die from prostate cancer [4].
Given the high rates of recurrence, development of metastatic disease,
and high burden of prostate cancer–specific deaths in men diagnosed
with high-risk prostate cancer and treated with radiotherapy plus ADT,
means by which to further intensify treatment are greatly needed. One
approach to improve outcomes in this setting is through identification
of molecular pathways whose targeting results in radiosensitization and/
or improved efficacy of antiandrogen therapy.
In analysis of results from a multi-institutional randomized trial
where men with prostate cancer were treated with RT + ADT,
increased murine double minute 2 (MDM2) expression was
demonstrated to increase the risk for recurrence, metastasis, and
death from prostate cancer independently of patient p53 status [7].
Consistent findings were also noted in a previous analysis of a smaller
cohort of men prospectively treated with RT + ADT [8]. The MDM2
human orthologue oncoprotein is a ubiquitin ligase which when
activated targets p53, among other clients, for degradation and also
represses p53 transcriptional targets, thereby acting as a negative
regulator of p53 [9–14]. Thus, overexpression of MDM2 results in
inactivation of the p53 pathway and inhibits p53-mediated cell cycle
arrest [15,16]. Antisense MDM2 knockdown sensitized prostate
cancer cell lines to radiotherapy, ADT, and the combination in a
p53-dependent and -independent manner [17–20], thus confirming
MDM2 as a therapeutic target for intensification in prostate cancer.
Indeed, the prototypical MDM2 small molecule inhibitor,
nutlin-3, induces radiosensitization to ADT in vitro and in vivo
[21,22]. However, nutlin-3 has poor pharmacokinetics, and similar
studies with clinically relevant MDM2 inhibitors have not been
performed. MI-219 is a small molecule inhibitor of MDM2 with
improved pharmacokinetics that has single-agent activity in vivo [23].
Therefore, we assessed the potential for MI-219, a clinically relevant
small molecule inhibitor of MDM2, to induce sensitization to
radiotherapy, antiandrogen therapy, and the combination therapy
in vitro and in vivo across multiple prostate cancer cell lines.Materials and Methods
Cell Culture and Cell Lines
Androgen-dependent (22RV1 and LNCaP) cell lines were
obtained from ATCC and maintained as per the guidelines. All cell
lines were purchased between January 2012 and June 2013. Before
the initiation of our analyses, all cell lines were authenticated,
characterized, and genotyped by fragment analysis and ProfilerID at
our DNA sequencing core facility. Sample fragments were compared
against the cell line standards provided by ATCC. Cells were cultured
at 37°C in a 5% CO2 humidified incubator. P53 knockdown cells
were generated by transfecting the cells with lentivrus-based shRNAs
(Addgene, Cambridge, MA, pLKO-p53-shRNA-427 [24]) and
growing them in puromycin containing media for 5 to 6 days. PC3
and DU145 cells were maintained in DMEM supplemented with
10% FBS. The p53 status and androgen sensitivity of the cell lines
used in the study are listed in Supplementary Table 1.
Immunoblot (Western Blot) Analysis
Western blot analysis was carried out using standard protocols.
Cells were grown in culture dishes and treated with indicated
treatments for designated time periods, and cell lysates were resolved
on SDS-PAGE gels to transfer on to polyvinylidene difluoride
membranes. Membranes were probed against specific primary
antibodies against p53 (Cell Signaling #9282), MDM2 (Santa Cruz
Biotech #SMP14), p21 (Cell Signaling #2947), PUMA (Cell
Signaling #4976), and GAPDH (Cell Signaling #2118), followed
by HRP-conjugated secondary antibodies. Membranes were visual-
ized using the Enhanced Chemiluminescence Western Blotting
System (GE Healthcare, Piscataway, NJ).
Clonogenic Survival Assays
Cells were trypsinized and plated in triplicate into six-well plates at
different densities based on cell types and doses of radiation. 22RV1,
LNCaP, DU145, and PC3 cells were plated at a density of 2000 to
10,000 cells/well, 100 to 600 cells/well, and 100 to 500 cells/well,
respectively. Cells were treated with 5 μMMI-219 for 2 hours and then
treated with radiation (2 to 6 Gy). Twenty-four hours after radiation
treatment, themedium containingMI-219was removed, and cells were
maintained in normal culturing medium. Twelve days after the cells
were plated, they were washed and stained with crystal violet, and the
colonies containing N50 cells were counted. Plating efficiency was
calculated by dividing the average number of cell colonies per well by
the amount of cells plated. Survival fractions were calculated by
normalization to the plating efficiency of appropriate control groups.
Immunofluorescence
22RV1 and LNCaP cells (with or without p53 knockdown) were
seeded onto coverslips in six-well plates and incubated overnight at
37°C. Cells were treated with either MI-219 or radiation or a
combination of both. Following the indicated treatment for the
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(50:50). Cells were washed three times with cold PBS and then
permeabilized with 0.5% Triton X-100 in PBS for 5 minutes at room
temperature. Cells were then blocked overnight at 4°C with blocking
buffer (0.1% Triton X-100, 1% BSA in PBS). Blocked cells were
incubated with anti–phospho-histone H2A.X (Ser139) monoclonal
antibody (Cell Signaling #9718) for 1 hour at a 1:10,000 dilution in
blocking buffer at room temperature. After washing three times with
washing buffer (0.1% Triton X-100 in PBS), cells were incubated for
1 hour at room temperature with Alexa Fluor 488 goat anti-rabbit
secondary antibody in blocking buffer. Cells were then washed with
PBS, and images were acquired.
Immunohistochemistry
Tumors from mice treated with MI-219 (300 mg/kg), radiation, or
a combination of both, and tumors from castrated mice were excised
and fixed in formalin. The tumors were processed at the Tissue Core
Facility of University of Michigan and stained with anti-CD31
antibody (1:100, Abcam #ab28364), and blood vessel density was
determined by manual counting at least five high-power fields. A
two-sided Student’s t test was performed to assess statistical significance.
Flow Cytometry
Cells were treated with MI-219 or radiation and collected after
indicated time points. Cells were washed with PBS and fixed in 1 ml of
cold 70% ethanol, added dropwise. Cells were then pelleted by
centrifugation and washed twice with PBS at RT. Cells were then
treated with 50 μl of ribonuclease A, after which propidium iodide was
added to cells. Cells were incubated for 15 minutes and were acquired
on FACSAria (BD biosciences) for the analysis of sub-G1 cells.
The Annexin V apoptosis assay was carried out using ApoScreen
Annexin V Apoptosis Kit (Southern Biotech) per the manufacturer's
protocol. Briefly, cells treated casodex (5 μM), MI-219 (10 μM) or
both, or were grown in charcoal-stripped media and treated with
MI-219. After the treatment, cells were washed with cold PBS,
suspended in cold 1× binding buffer, stained with Annexin V and
propidium iodide, and subjected to flow cytometry by FACSAria Cell
Sorter (BD Biosciences).
Reporter Assays
The MDM2 or p21 3′UTR subcloned into the pRL-TK vector.
22RV1, LNCaP (with or without p53-KD), and DU145 cells were
plated onto 24-well plates and transfected with these 3′UTR
luciferase constructs as well as pRL-TK vector as internal control
for luciferase activity. After 48 hours of incubation, luciferase reporter
assay were conducted with the dual luciferase assay kit (Promega,
Madison, WI) as per the recommended protocol.
In Vivo Xenograft Studies
Xenograft studies were performed in accordance with National
Institutes of Health guidelines, and animal protocols were approved
by the University of Michigan. 22RV1 or 22RV1 p53-KD cells (3 ×
106) were combined 1:1 with Matrigel (BD Biosciences, 354234)
and injected subcutaneously into the flanks of 6-week-old,
intact-male athymic nude/SCID mice. Once the tumors reached
100 mm3 in size, mice were subjected to treatment with radiation
(delivered in four fractions of 2 Gy on days 1 to 4), MI-219 (delivered
orally at 300 mg/kg twice daily on days 1 to 10), or both. Tumor sizes
were measured for 18 days following a 2-week engraftment period.For VCaP xenografts studies, VCaP (3 × 106) cells were injected
subcutaneously into the dorsal flanks of male athymic nude/SCID
mice, and tumors were allowed to grow. Treatment was initiated
when tumors were approximately 100 mm3 in size. Radiation was
delivered on days 0, 2, and 4, with 2 Gy delivered on each of these
days for a total dose of 6 Gy. Castration was performed on day 0.
MI-219 was given orally at a dose of 100 mg/kg for 20 consecutive
days beginning on day 0. Tumor growth was followed for 91 days
posttreatment. Graphs were plotted using Graphpad prism.
Statistical Analysis
All data are expressed as means ± SD or SEM. All experimental
assays were performed in duplicate or triplicate. Statistical analysis was
performed by two-sided Student’s t test and one-way analysis of
variance with a Student-Newman-Keuls follow-up test. Significance
was indicated by “*” when P b .05.
Results
MI-219 Results in p53 Activation in a Dose- and
Time-Dependent Manner
To assess the dose and time response to MI-219, we used two
wt-p53 PCa cell lines as well as their corresponding p53-knockdown
(p53-KD) cell lines. LNCaP and 22RV1 cell lines (wt-p53) treated
with increasing doses of MI-219 (2 to 10 μM) demonstrated a
dose-dependent increase in MDM2 and p53, as well as p53 targets
p21, and the proapoptotic protein PUMA (p53 upregulated
modulator of apoptosis), with a maximum effect noted between 2
and 5 μM (Figure 1, A and B). Knockdown of p53 using specific
lentiviral-based shRNAs resulted in undetectable levels of p53 in both
cell lines with corresponding downregulation of the p53-regulated
proteins p21 and PUMA (Supplementary Figure S1, A and B).
Given the apparent p53-dependent dose response to MI-219 as
demonstrated in the wt-p53 and p53-KD LNCaP and 22RV1 cell
lines, we next assessed the dose response to MI-219 in three PCa cell
lines with altered p53 status. PC3 (p53 null), DU145 (p53
homozygous mutant), and VCaP (p53 heterozygous mutant) cell
lines were treated with increasing doses of MI-219 (Figure 1, C–E).
As expected, p53 was undetectable in the p53 null PC3 line, and p53
levels were not significantly altered in the DU145 and VCaP cell
lines. p21, a known p53-independent client of MDM2 [25], showed
dose-dependent increase in levels across these cell lines. Interestingly,
the VCaP cell line exhibited an apparent active p53 response with
regard to dose-dependent increase in levels of MDM2 and PUMA
expression, suggesting at least partial p53 functionality in this mutant.
Promoter assay analysis confirmed this functional p53 response in the
VCaP cell line (Supplementary Figure 1).
Having established a p53-dependent dose response, we next
evaluated for a time-dependent response in the cell lines described
above. Cells were assayed at 2, 8, and 24 hours following
treatment with 10 μM MI-219 (Figure 1, F–J). In the wt-p53
22RV1 line, p53, p21, and PUMA levels increased over 24 hours,
whereas these levels peaked around 2 hours posttreatment in the
LNCaP line. This time-dependent response was greatly diminished
in the 22RV1 and LNCaP p53-KD cell lines (Supplementary
Figure 2, A–D); however, there was a modest increase of expression of
p21 at 24 hours posttreatment in the p53-KD lines, again consistent with
p21 being a target of MDM2. The p53 null cell line, PC3, also showed a






Figure 1.MI-219 results in p53 activation in a dose- and time-dependent manner. (A–E)Western blot analyses of prostate cancer cells treated
with indicated doses of MI-219 or nutlin-3. (F–J) Cells were treated with 10 μMMI-219 or nutlin-3 for indicated time points, and Western blot
analysis was carried out. GAPDH documented equal loading. (K) 22RV1and LNCaP cells, with or without p53 knockdown, were treated with
increasingdosesofMI-219 andnutlin-3 in aWST-1 cytotoxicity assay. (L) cellswith alteredp53status (PC3,DU145, andVCaP)were treatedwith
increasing doses of MI-219 in a similar fashion to determine IC50 values of MI-219. Bars represent ± SEM of three independent experiments.
216 MDM2 Radiosensitizes p53-Intact Prostate Cancers Feng et al. Neoplasia Vol. 18, No. 4, 2016p53-dependent time response with regard to MDM2 and PUMA
expression.
We next assessed the effect of MI-219 on cellular proliferation.
(Figure 1, K and L). The wt-p53 22RV1 and LNCaP cell lines hadsimilar responses to treatment with MI-219, with IC50 values
between 2 and 6 μM, which was similar to the IC50 values for
nutlin-3 (ranging from 9 to 13 μM). The p53-KD correspondents







Figure 2.MI-219 radiosensitizes prostate cancer cells in a p53-dependentmanner. (A)Western blot analysis of LNCaPcells after treatmentwith
10μMMI-219and/or 10Gyof radiation. (B)Clonogenic survival assaysof LNCaPcells after treatmentwith either 10μMMI-219or 10μMnutlin-3
and radiation (0, 2, 4, and 6Gy). (C) Apoptosis (sub-G1 population) was analyzed in LNCaP cells after treatmentwith 10 μMMI-219, radiation (10
Gy), or both via FACS analysis. (D–E) Similar experiments were performed with LNCaP p53 knockdown cells. (F–P) Western blot analyses,
clonogenic cell survival assays, and quantification of apoptotic cells were carried out in a similar fashion in 22RV1, PC3, and DU145 cells.
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a response more similar to the p53-KD cell lines with an IC50 value of
22.39 μM. In total, these findings suggest a definite p53-dependent
dose and time response and a p53-dependent cell survival response to
MDM2 inhibition with MI-219.
MI-219 Radiosensitizes Prostate Cancer Cells in a
p53-Dependent Manner
Radiation therapy forms a major treatment modality in the clinical
management of prostate cancer. Thus, compounds that can sensitize
prostate cancer cells to radiation doses are of high clinical importance.
To determine if MI-219 sensitizes prostate cancer cells to ionizing
radiation, we next sought to assess the impact of combining
inhibition of MDM2 via MI-219 with radiation through clonogenic
survival assays and analysis of sub-G1 DNA content as a marker of
apoptosis. For clonogenic survival analysis, cells were treated with
MI-219 or radiation as described in methods. The timing of
administration of MI-219 was not found to be schedule dependent
(Supplementary Figure 3). The combination of MI-219 and radiation
resulted in upregulation of p53, p21, and PUMA (Figure 2, A and F)
in the wt-p53 22RV1 and LNCaP cell lines. Treatment with MI-219
in addition to radiation resulted in significant radiosensitization, with
radiation enhancement ratios of 1.30 (SD 0.07) for 22RV1 and 1.35
(SD 0.05) for LNCap (Figure 2, B and G). We next asked if
treatment with MI-219 and/or radiation results in increased apoptosis
of cells and if the apoptosis is p53 dependent. DNA content was
determined via flow cytometry following treatment with 5 μM
MI-219 with and without radiation (10 Gy). We found an increased
sub-G1 DNA content at 72 hours for 22RV1 and LNCaP cell lines
following treatment with RT alone, MI-219 alone, and RT +
MI-219. The combinatorial treatment of MI-219 and radiation
further resulted in a significant increase in sub-G1 DNA content
compared with treatment with single therapy (Figure 2, C and H).
The addition of MI-219 to radiation did not result in radio-
sensitization in the p53-KD 22RV1 and LNCaP cell lines, or in the
PC3 or DU145 cell lines (Figure 2, E, J, M, and P). Similarly,
upregulation of p53, p21, and PUMA was lost in PC3 or DU145 cell
lines. p53-KD LNCaP and PC3 cell lines showed no increase in
sub-G1 DNA content at 72 hours, whereas the p53-KD 22RV1 and
DU145 cell lines had an increase in sub-G1 DNA content following
treatment with radiation with minimal impact with the addition of
MI-219 to radiation. Taken together, these results suggest that
MDM2 inhibition via MI-219 sensitizes prostate cancer cells to
ionizing radiations in a p53-dependent manner.
The Combination of MI-219 and Radiation Results in
a p53-Dependent Increase in DNA Damage
Although the addition of MI-219 to radiation resulted in a
significant increase in apoptosis, it is unlikely that this finding alone is
responsible for the radiation enhancement observed with MDM2
inhibition. To further ascertain the mechanism of MDM2
inhibition–induced radiosensitization, we evaluated unrepaired
DNA damage following treatment with RT, MI-219, and RT +
MI-219 at 30 minutes and 24 hours posttreatment via γ-H2AX foci
formation in wt-p53 and p53-KD 22RV1 and LNCaP cell lines.
Treatment with MI-219 alone resulted in a moderate increase in the
number of γ-H2AX foci at 24 hours posttreatment in both wt-p53
cell lines (Figure 3A and C). The addition of MI-219 to radiation
caused a significant increase in the percentage of γ-H2AX foci–positivecells at 30 minutes and 24 hours posttreatment in the wt-p53 22RV1
cell line and at 30 minutes posttreatment in the wt-p53 LnCaP cell line
compared with treatment with radiation alone. Knockdown of p53
abolished these findings (Figure 3, B and D).
MI-219 Causes In Vivo Radiosensitization in a
p53-Dependent Manner
Having defined the p53-dependent radiosensitization of MI-219
in vitro, we sought to verify these findings in a 22RV1 mouse
xenograft model. Animal groups were treated with RT alone, MI-219
alone, or the combination of the two and compared with a control
group, which received no treatment. The treatment with radiation or
MI-219 was given as described in methods. Tumor sizes were
measured two to three times a week following a 2-week engraftment
period. Single-modality treatment with radiation or MI-219 resulted
in equivalent tumor growth delay in the wt-p53 22RV1 model
(Figure 4A). The combination of radiation and MI-219 resulted in a
statistically significant decrease in tumor growth that was evident by
day 4 and persisted through day 18. In the p53-KD 22RV1
xenografts, there were no response to treatment with MI-219 and no
enhancement when MI-219 was combined with RT (Figure 4C).
These results indicate the promise of MI-219 in sensitizing prostate
cancer tumors with wt-p53 to ionizing radiations in vivo.
Androgen Receptor Antagonism Combined with MI-219
Treatment Results in Increased Apoptotic Cell Death in a
p53-Dependent Manner
Androgen deprivation combined with radiation therapy is a
standard treatment modality for high-risk prostate cancer. Given the
demonstrated p53-dependent benefits of MI-219 when combined
with radiation, we next evaluated the impact of combining MI-219
with androgen deprivation therapy in vitro. 22RV1 and LNCaP
(both androgen responsive) wt-p53 and p53-KD cell lines were
treated with 5 μM casodex (a clinically available antiandrogen with
mixed agonist/antagonist effects) or 10 μMMI-219, or evaluated in a
charcoal-stripped media to simulate androgen withdrawal. Cells were
also treated with paired combinations of these three modalities.
Antagonism of the androgen receptor with either charcoal-stripped
media or casodex resulted in a p53-dependent activation of p53, p21,
and PUMA that was enhanced with the addition of MI-219
(Supplementary Figure 4, A and B). Next, we assessed apoptosis via
analysis of Annexin V following treatment with casodex/charcoal-
stripped media, MI-219, or the combination of two in wt-p53
22RV1 and LNCaP cell lines, p53-KD 22RV1 and LNCaP cell lines,
and VCaP, PC3, and DU145 cell lines (Figure 5, A and B). The
combination of MI-219 with casodex or charcoal-stripped media
resulted in a statistically significant increase in the number of Annexin
V–positive cells in the wt-p53 22RV1, wt-p53 LNCaP, and VCaP
cell lines compared with treatment with androgen deprivation or
MI-219 alone, demonstrating a p53-dependent increase in apoptosis.
This increase in apoptosis was not noted in the p53-KD cell lines or in
the PC3 or DU145 cell lines.
MI-219 Enhances the Effects of Combined Radiation
and Androgen-Deprivation Therapy In Vivo
Androgen deprivation therapy and radiation are the standard of
care for clinical management of prostate cancer. Given the findings
that MI-219 can increase the effect of both of these treatment




Figure 3.MI-219 increases DNA damage in a p53-dependent manner. Foci formation assays were conducted on (A–B) 22RV1 cells with or
without p53 knockdown and (C–D) LNCaP cells with or without p53 knockdown. Cells were treated with 10 μMMI-219, radiation (10 Gy),
or both and stained for H2Ax phosphorylation ( H2AX) at indicated time points. Graphs represent the quantification of cells with positive
H2AX foci. Bars represent ± SEM.
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xenograft model was established with six to eight animals in each
treatment group. Animal groups were treated with RT alone, MI-219
alone, castration alone, RT + castration, RT + MI-219, castration +
MI-219, and RT + castration + MI-219. Single therapy with either
RT or castration was equivalent in delaying tumor growth, slightly
outperforming therapy with MI-219 alone (Figure 6A). Combination
therapy with RT + castration, RT +MI-219, and castration + MI-219all delayed tumor growth similarity, outperforming any single-
modality treatment. Triple therapy substantially delayed tumor
growth compared with all other treatment combinations and appears
to have a greater than additive effect on tumor growth delay. Triple
therapy resulted in near-complete regression of the tumor at 50 days
and only a 1.5-fold increase from initial tumor volume at 91 days
posttreatment. As expected, MI-219, radiation, or a combination of
two, as well as the triple therapy, resulted in an increase in p53 levels
A B
Figure 4. MI-219 radiosensitizes prostate cancer xenografts in a p53-dependent manner. Xenografts arising from (A) 22RV1 cells or (B)
22RV1 (p53 knockdown) cells were treated with MI-219 (300 mg/kg body weight), radiation (four fractions of 2 Gy on days 1 to 4), or a
combination of both, and tumor growth was monitored for 18 days. Bars represent ± SEM.
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sensitization to radiotherapy and antiandrogen therapy, we saw that
treatment response correlated well with blood vessel densities as
indicated by CD31 staining [26]. Whereas single therapies resulted in
a slight decrease in the vessel density, a combination of MI-219 with
radiation or castration was more effective in reducing the density of
blood vessels. Interestingly, the triple therapy outperformed all the
therapies and resulted in a drastic reduction of blood vessel density,
indicating the effectiveness of the combination of MI-219 with
radiation and ADT (Figure 6C).
Discussion
Although mutations of the TP53 gene, which encodes the tumor
suppressor p53 protein, are thought to be the most abundant genetic
alterations occurring in cancer, the relative prevalence of p53 mutations
in clinically localized prostate cancer is low [27–30]. Thus, although
the presence of p53 mutations in localized prostate cancer has been
associated with worse overall patient outcomes for men treated with
radiation plus androgen deprivation, approximately 80% of men
diagnosed with prostate cancer will not harbor such a mutation [28–A
Figure 5. Androgen receptor antagonism combined with MI-219 trea
manner. Apoptosis measured by Annexin V in multiple cell line
charcoal-stripped medium, MI-219 or both. *P b .05.30]. However, even cancers, which harbor wild-type p53, may have a
reduced or inhibited function of p53. This inhibition is most
commonly due to increased expression of MDM2, a ubiquitin ligase
with both p53-dependent as well as -independent functions. MDM2
overexpression in prostate cancer has also been shown to be associated
with worse clinical outcomes [7]. In analysis of 478 men treated with
conventional dose radiation plus short- or long-term androgen
deprivation on Radiation Therapy Oncology Group 92-02 [4],
overexpression of MDM2 was prognostic for development of
metastatic disease as well as overall mortality, with a trend toward
cause-specific survival as well [7,31]. Notably, approximately 24% of
men in this analysis were found to overexpress MDM2. Combined
together, the above observations suggest that inhibition of MDM2 in
prostate cancer may have a dual suppressive effect by virtue of blocking
MDM2 function and activating p53 functions. Thus, MDM2
inhibition represents an attractive and viable strategy for the treatment
of cancers with infrequent p53 alterations, such as prostate cancer,
especially in combination with current standard of care therapies.
Along with this enthusiasm, there are important questions about
MDM2 inhibition therapy that remain to be answered. For example,B
tment results in increased apoptotic cell death in a p53-dependent
s after treatment with (A) MI-219, casodex, or both and (B)
A B
C
Figure 6. MI-219 enhances the effects of combined radiation and androgen-deprivation therapy in vivo. (A) VCaP xenografts were
subjected to indicated treatments, and tumor growth was monitored. Graphs represent the fold change of tumor volumes, normalized to
initial tumor volume. (B) Western blot analyses of p53 in the treated xenograft samples (two independent xenografts per treatment are
shown). (C) Xenografts were formalin fixed, sectioned, and stained with CD31 antibodies to quantitate the blood vessel densities after the
treatments. *P b .05 compared with triple therapy. ** P b .05 compared with double therapy.
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aberrations or mutations in the p53 pathway, as there is some
evidence that leukemic cells can acquire p53 mutations during
treatment with MDM2 inhibitors [32]; whether this is true for
prostate cancer or other solid tumors is unknown. It is also very
important to assess if there are other pathways that cancer cells may
use after anti-MDM2 therapy to evade the treatment. Finally,
although the MDM2 inhibition seems to be effective in tumors with
intact p53 functions, it will be interesting to design combination
therapies that can use MDM2 inhibition in cancers with mutant
p53 functions.
In the present study, we demonstrate that inhibition of MDM2
results in in vitro and in vivo p53-dependent radiosensitization of
prostate cancer cells. Cell lines harboring wt-p53 or mutated yet
functional p53 signaling displayed a time- and dose-dependent
upregulation of p53, p21, and PUMA following inhibition of
MDM2, and inhibition ofMDM2 likewise resulted in a p53-dependent
decrease in clonogenic cell survival. Mechanistically, radiosensitization
following inhibition of MDM2 was largely due to p53-dependent
increases inDNAdamage and apoptosis. CombiningMDM2 inhibitionwith androgen deprivation therapy similarly resulted in a p53-dependent
upregulation of p53, p21, and PUMA, as well as increased rates of apoptosis.
Finally, triple therapy consisting of radiation therapy, androgen deprivation,
and MDM2 inhibition substantially decreased xenograft tumor growth
compared with any single- or double-agent treatment. In total, these findings
underscore the potential of MDM2 inhibition as a means of inducing
sensitization to both radiation and androgen deprivation therapy and thereby
improving clinical outcomes in prostate cancers with functional p53 status.
The biggest strength of our study lies in the clinical relevance of our
findings, which support MDM2 inhibition with MI-219 as a strategy
for therapy intensification in prostate cancer. Although MI-219 has
suboptimal dosing and delivery characteristics, SAR405838, an
analogue of MI-219 with improved pharmacokinetic profile, has
shown remarkable single-agent efficacy in multiple xenograft tumor
models and is being evaluated in humans [33]. Thus, our study
provides a strong rationale for investigating SAR405838 in clinical
trials of ADT and/or radiotherapy combinations in prostate cancer.
The combination of low prevalence of p53 mutations in localized
prostate cancer, worse clinical outcomes with MDM2 overexpression,
and the unacceptably high recurrence of localized high-risk prostate
222 MDM2 Radiosensitizes p53-Intact Prostate Cancers Feng et al. Neoplasia Vol. 18, No. 4, 2016cancer, indicates that inhibition of MDM2 may serve as a means by
which improved outcomes for high-risk localized prostate cancer can
be achieved.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2016.01.006.
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